Abcam

97 articles about Abcam

• ABCAM PLC Result of Annual General Meeting - May 17, 2023

  5/17/2023

  Abcam plc, a global leader in the supply of life science research tools, announces the voting results from the Annual General Meeting.

• Abcam PLC: Statement on potential Extraordinary General Meeting

  5/17/2023

  Abcam plc, a global leader in the supply of life science research tools, notes that its founder and former director Dr. Jonathan Milner has indicated he will take steps to call an extraordinary general meeting of the Company's shareholders to elect himself to the Company's Board of Directors as Executive Chairman.

• ABCAM PLC Comments on Investor Engagement

  5/1/2023

  Abcam plc, a global leader in the supply of life science research tools, notes the Form 13D filed by founder and former director Dr Jonathan Milner and related press reports.

• ABCAM PLC: Trading Update

  4/13/2023

  Abcam plc, a global leader in the supply of life science research tools, provides the following preliminary trading update for the quarter ending 31 March 2023.

• Abcam, plc Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting

  3/30/2023

  Abcam plc announces that, following release on 20 March 2023 of its final results for the year ended 31 December 2022 on Form 20-F with the Securities and Exchange Commission, the Abcam plc Annual Report and Accounts 2022 have been published and are available on the Abcam plc website

• ABCAM PLC: Final results for the year ended 31 December 2022

  3/20/2023

  Abcam plc today announces its results for the year ended 31 December 2022 (the 'period').

• ABCAM PLC: Trading Update - Jan 30, 2023

  1/30/2023

  Abcam plc, a global leader in the supply of life science research tools, provides the following preliminary trading update for the year ending 31 December 2022.

• Abcam plc: Update on AIM Delisting

  12/12/2022

  Abcam plc, and, a global leader in the supply of life science research tools, provides a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM, as originally announced on 17 October 2022.

• ABCAM PLC: Result of General Meeting - Shareholders approve AIM Delisting

  11/11/2022

  Abcam plc, a global leader in the supply of life science research tools, announces that the resolution put to its General Meeting held today for the cancellation of the admission of its Ordinary Shares to trading on AIM was passed.

• NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research

  11/9/2022

  NanoString Technologies, Inc. and Abcam announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString’s high-plex spatial multiomic solutions.

• ABCAM PLC: Interim results for the six-month period ended 30 June 2022

  9/12/2022

  Abcam plc announces its interim results for the six-month period ended 30 June 2022.

• Abcam: Appointment of Vice President of Investor Relations

  6/27/2022

  Abcam plc, a global leader in the supply of life science research tools, announces the appointment of Tommy Thomas as Vice President of Investor Relations.

• Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021

  3/14/2022

  Abcam plc, a global leader in the supply of life science research tools, announces its final results for the 18-month period ended 31 December 2021.

• Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications

  2/1/2022

  Twist Bioscience Corporation and Abcam announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic and research applications.

• 

  Life Sciences Companies Leverage New Partnerships Against Severe Diseases

  2/1/2022

  Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1. 

• Alamar Biosciences partners with Abcam to drive understanding of the human proteome

  1/4/2022

  Alamar selects Abcam as a key provider of antibody content for its propriety NULISA technology platform.

• Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

  11/2/2021

  Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam, a global innovator in life sciences research tools, announced a strategic development and supply partnership.

• 29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases

  9/13/2021

  Abcam plc, a global leader in the supply of life science research tools, announces its interim results for the six- and 12-month periods ended 30 June 2021.

• Abcam to Acquire BioVision for $340 million

  8/2/2021

  Abcam plc, a global leader in the supply of life science research tools, announces that it has entered into a definitive agreement to acquire BioVision, Inc., a wholly owned subsidiary of Boai NKY Medical Holdings Ltd., for $340 million.

• Abcam and MEDx extend precision medicine strategic partnership

  4/12/2021

  Abcam, a global innovator in life science reagents and tools, and MEDx Translational Medicine, formerly QIAGEN Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market.